Follow The Filings

CRBP Corbus Pharmaceuticals

Corbus Pharmaceuticals earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by CRBP's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CRBP insider trades
  • $126K bought by 1 insider
  • $344K sold by 1 insider outside a trading plan
  • $1.1M sold by 6 insiders under 10b5-1 plans
  1. Yong Ben Director
    Planned sale
    $16K 2,000 shares at $7.84 18% of stake
    Traded Sep 14 Filed Sep 15
  2. Nishant C Saxena Chief Business Officer
    Buy
    $25K 2,600 shares at $9.63 +3.5% to stake
    Traded Aug 11 Filed Aug 12
  3. Yuval Cohen CEO
    Planned sale
    $171K 17,000 shares at $10.08 9.8% of stake
    Traded Aug 7 Filed Aug 10
  4. Sean F. Moran CFO
    Planned sale
    $121K 12,000 shares at $10.08 12% of stake
    Traded Aug 7 Filed Aug 10
  5. Winston Kung Director
    Planned sale
    $16K 2,026 shares at $7.91 14% of stake
    Traded Jun 10 Filed Jun 11
  6. John Kenneth Jenkins Director
    Planned sale
    $38K 4,800 shares at $7.91 56% of stake
    Traded Jun 10 Filed Jun 11
  7. Anne Altmeyer Director
    Planned sale
    $19K 2,412 shares at $7.91 24% of stake
    Traded Jun 10 Filed Jun 11
  8. Nishant C Saxena Chief Business Officer
    Buy
    $101K 13,500 shares at $7.50 +22% to stake
    Traded Jun 2–3 Filed Jun 3
  9. Cormorant Asset Management, LP 10% owner, +2 joint filers
    Sale
    $344K 30,029 shares at $11.46 1.3% of stake
    Traded Dec 11, 2025 Filed Dec 15, 2025
  10. Yuval Cohen CEO
    Planned sale
    $471K 27,633 shares at $17.05 17% of stake
    Traded Oct 24–27 Filed Oct 27, 2025
  11. Sean F. Moran CFO
    Planned sale
    $221K 12,981 shares at $17.02 15% of stake
    Traded Oct 24, 2025 Filed Oct 27, 2025
  12. Anne Altmeyer Director
    Planned sale
    $22K 1,060 shares at $20.50 15% of stake
    Traded Oct 20, 2025 Filed Oct 21, 2025

Also filed in the last 12 months, not counted as buying or selling: 12 stock grants, 6 sales to cover taxes, and 3 option exercises.

SEC filings

Recent issuer filings from EDGAR, 24 shown.

Filed Form Detail Links
8-K 7.01,9.01
SCHEDULE 13G —
8-K 7.01,8.01,9.01
SCHEDULE 13G/A —
424B5
8-K 2.02,7.01,9.01
10-Q
SCHEDULE 13G —
8-K 1.01,7.01,9.01
8-K 7.01,8.01,9.01
8-K 1.01,5.02,7.01,9.01
SCHEDULE 13G/A —
8-K 5.02,5.07,7.01,9.01
8-K 2.02,7.01,9.01
10-Q
8-K 5.02,9.01
DEFA14A
8-K 7.01,8.01,9.01
8-K 5.02,7.01,8.01,9.01
DEF 14A
DEFA14A
424B3
8-K 2.02,7.01,9.01
10-K

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.